Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy

07-Jan-2013 - Germany

Evotec AG announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer.

Apeiron Biologics will contribute in vitro and in vivo pharmacology expertise to this collaboration while Evotec will be responsible for medicinal chemistry as well as chemical proteomics.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances